QTREX Quantum grants director 550K RSUs award

QTREX Quantum Ltd. (QTEX) reported that director Parnes Tal received a grant/award acquisition of 550,000 Ordinary Shares in the form of Restricted Share Units under the company’s 2019 Plan.

Rhea-AI Filing Summary

QTREX Quantum Ltd. (QTEX) reported that director Parnes Tal received a grant/award acquisition of 550,000 Ordinary Shares in the form of Restricted Share Units under the company’s 2019 Plan. After this award, Tal directly holds 760,000 Ordinary Shares, subject to a multi‑year vesting schedule.

The RSUs vest 33.34% on the first anniversary date following July 1, 2026, with the remaining 8.33% vesting quarterly over 8 quarters. The grant was approved by shareholders at an Extraordinary General Meeting on August 28, 2026.

Insider Trade Summary

Grant/Award: 550,000 shares

Grant/Award 1 txn

Insider Parnes Tal

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1	550,000	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 760,000 shares (Direct)

Footnotes (1)

1. F1. The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: (i) 33.34% of the RSUs will vest on the first anniversary date following July 1, 2026 (the "First Instalment"); and (ii) 8.33% of the RSUs will vest on a quarterly basis over 8 quarters (two (2) years), following the First Instalment. The grant of RSUs was approved by the Company's shareholders at an Extraordinary General Meeting of Shareholders held on August 28, 2026.

Key Figures

RSUs granted: 550,000 Ordinary Shares Shares held after transaction: 760,000 Ordinary Shares Initial vesting percentage: 33.34% +5 more

8 metrics

RSUs granted 550,000 Ordinary Shares Grant/award acquisition to director Parnes Tal on 2026-08-28

Shares held after transaction 760,000 Ordinary Shares Direct ownership by Parnes Tal following the RSU grant

Initial vesting percentage 33.34% Portion of RSUs vesting on first anniversary date following July 1, 2026

Subsequent quarterly vesting percentage 8.33% RSUs vesting each quarter over 8 quarters after first vesting

Number of vesting quarters 8 quarters Quarterly vesting period for remaining RSUs over two years

Reference date for first vesting July 1, 2026 First anniversary date following this date triggers initial vesting

Shareholder approval date August 28, 2026 Extraordinary General Meeting approving the RSU grant

Transaction price per share $0.0000 RSU grant with no cash price per share

Key Terms

Restricted Share Units ("RSUs"), 2019 Plan, Extraordinary General Meeting of Shareholders

3 terms

Restricted Share Units ("RSUs") financial

"The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s 2019 Plan"

2019 Plan financial

"were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan"

Extraordinary General Meeting of Shareholders regulatory

"approved by the Company's shareholders at an Extraordinary General Meeting of Shareholders"

A meeting called by a company outside its regular annual meeting to address urgent or special matters that cannot wait until the next scheduled meeting. Investors attend or vote to decide on actions such as major deals, leadership changes, capital-raising, or rule changes; think of it as an emergency board meeting where shareholders have a direct say and the outcomes can quickly change a company’s strategy, ownership stakes, or financial prospects.

FAQ

What insider transaction did QTEX director Parnes Tal report?

Director Parnes Tal reported a grant/award of 550,000 Ordinary Shares in the form of RSUs under QTREX Quantum Ltd.’s 2019 Plan, bringing his direct holdings to 760,000 Ordinary Shares, subject to vesting conditions.

How many QTEX shares does Parnes Tal hold after this transaction?

After the grant, Parnes Tal directly holds 760,000 Ordinary Shares of QTREX Quantum Ltd. These holdings reflect the RSU award and are subject to the stated vesting schedule.

What is the vesting schedule of the 550,000 QTEX RSUs granted to Parnes Tal?

Of the 550,000 RSUs, 33.34% will vest on the first anniversary date following July 1, 2026. The remaining 8.33% will vest on a quarterly basis over 8 quarters (two years) after that first vesting date.

Under which plan were the QTEX RSUs to Parnes Tal granted?

The RSUs granted to Parnes Tal were issued under QTREX Quantum Ltd.’s 2019 Plan, which governs the company’s equity-based compensation awards.

Who approved the RSU grant to QTEX director Parnes Tal and when?

The grant of RSUs to Parnes Tal was approved by the company’s shareholders at an Extraordinary General Meeting of Shareholders held on August 28, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:08 PM Accepted by SEC EDGAR 09/01/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parnes Tal

(Last) (First) (Middle)

2 ILAN RAMON ST.

(Street)

NESS-ZIONA 7492625

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
QTREX Quantum Ltd. [ QTEX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/28/2026		A		550,000(1)	A	$0	760,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: (i) 33.34% of the RSUs will vest on the first anniversary date following July 1, 2026 (the "First Instalment"); and (ii) 8.33% of the RSUs will vest on a quarterly basis over 8 quarters (two (2) years), following the First Instalment. The grant of RSUs was approved by the Company's shareholders at an Extraordinary General Meeting of Shareholders held on August 28, 2026.

	/s/ Tal Parnes	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)